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Background: To evaluate whether abnormal endothelial function, a common finding in gestational diabetes
mellitus (GDM) pregnancies, can be explained by inflammatory cytokines.
Methods: Forearm skin blood flow (FSBF), into response to acetylcholine (Ach) (endothelium-dependent
vasodilatation), were measured in 24 pregnant control subjects and 28 gestational diabetes mellitus (GDM) women,
in the third trimester of gestation. A fasting glycemic and lipidic panel was obtained, and inflammatory cytokines
(TNF-α and IL-6) and adiponectin were determined.
Results: FSBF is significantly reduced in GDM group compared with control subjects (344.59 ± 57.791 vs.176.38 ±
108.52, P < 0.05). Among all subjects, FSBF showed a strong negative correlation with TNF-α and IL-6 (r = −0.426,
P < 0.0001 and r = −0.564, P < 0.0001, respectively) and positive correlation with adiponectin (r = 0.468, P < 0.0001).
Conclusions: Endothelial function, an early marker of macrovascular disease, is present in non-obese pregnancies
complicated by GDM. This alteration seems to be directly related to inflammatory status, which may represent a
patho-physiological link between GDM and type 2 diabetes and, later on, metabolic syndrome.
Keywords: Forearm skin blood flow, Laser Doppler flowmetry, Gestational diabetes mellitus, InflammationIntroduction
Gestational diabetes mellitus (GDM), is one of the most
commonly observed obstetrical complications affecting
from 5% to 8% of all pregnancies [1,2].
GDM is associated with the development of inflam-
mation [3], where adipose tissues play an important
role in the regulation of insulin sensitivity by secreting
adipokines which are involved in the pathogenesis
pregnancy-induced insulin resistance, in the case of
obese pregnancies [4-6]. However, obesity may be not
the only link between inflammation and glucose in-
tolerance during pregnancy, placenta is also an import-
ant source of cytokines [7].* Correspondence: ines.mrizak@hotmail.com
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reproduction in any medium, provided the orMany studies suggest that GDM is characterized by
the installation of subclinical inflammation associated
with a vascular dysfunction due to the insulin resist-
ance, but to date there has been a dearth of studies,
evaluating cytokine levels in women with GDM in order
to explain their contribution to endothelium dysfunc-
tion [7]. Non-invasive measurement of microcirculatory
blood flow in patients has recently emerged as useful
tool to investigate the effect of insulin resistance on
endothelial function [8,9].
We have conducted the present study to assess
whether non-obese GDM women present an impair-
ment of endothelial NO release; we wanted to focus us
on the only effect of diabetes on the inflammatory status
and its impact on endothelial function. Hence, we have
investigated the endothelium-dependent vasodilatation
by measuring non-invasively the change of FSBF inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Mrizak et al. Lipids in Health and Disease 2013, 12:93 Page 2 of 7
http://www.lipidworld.com/content/12/1/93response to graded infusion of acetylcholine (Ach). We
have also assessed whether the inflammatory cytokine
levels can be involved in the impairment of endothelial
function.Methods
Subjects
The study was conducted in the Physiology and Func-
tional Explorations Department, University Farhat Hached
Hospital, Sousse, Tunisia, and it was approved by Farhat
Hached Hospital Ethical Committee for research on
humans in Tunisia. An informative written consent was
approved and signed by all the women of the study.
A total of 28 GDM patients were selected between
June 2010 to June 2011, from High Risk Pregnancy De-
partment, Farhat Hached Maternity. Inclusion criteria
were the following: normal glucose tolerance in early
pregnancy, diagnosis of GDM in the 2nd or the 3rd tri-
mester of gestation, according to the criteria of National
Diabetes Data Group [10], the age range was between 20
and 39 years and gestational age was between 28th and
41th week of gestation.
The gestational age was derived from the last men-
strual period, otherwise, gestational age was corrected
on the basis of ultrasonographic measurements, conson-
ant with clinical practice.
The selection of control individuals was from among
pregnant women with the same characteristics including
similar anthropometric parameters and gestational age,
but with normal glucose tolerance. Hence, O’Sullivan
test was conducted between the 24th and 26th week of
gestation [11]. A total control subjects enrolled in the
study was 24 pregnant women. Under the same condi-
tions as the diabetic group we collected anthropometric
measures of control group. The controls were measured
in an earlier gestational week in order to eliminate any
eventuality that controls may have glucose intolerance
before it was based on monitoring records in High Risk
Pregnancy Department, Farhat Hached Maternity. An
O’Sullivan test was conducted between the 24th and 26th
week of gestation.
Each of the 52 pregnant women who completed the
study was first asked to provide details of medical and
smoking history and then participated in health
screening session and overall medical examination, in-
cluding anthropometric measurement and resting ar-
terial blood pressure.
In recruiting patients we held that the patients showed
no risk to develop a preeclampsia, we followed the
screening adopted by the High Risk Pregnancy Depart-
ment, Farhat Hached Maternity, namely systolic blood
pressure 120 mmHg and diastolic blood pressure 90
mmHg, and negative proteinuria because it will be inthe risk of influence endothelial function. And all GDM
were monitored by insulin treatment.
All pregnancies were conducted under optimal condi-
tions, all deliveries are vaginal, and took place between
36 and 41 weeks, with no special feature of fetal growth
(data is not shown).
Biochemical parameters
Blood samples were collected from subjects after 12 hours
overnight fast, the blood was maintained at 4°C cen-
trifuged, distributed in aliquots and stored at −80°C until
the batched measurement of parameters. Serum total
cholesterol (TC) and triglycerides (TG) were determined
by standard assays. High-density lipoprotein cholesterol
(HDL) was measured by direct assay. Low-density lipopro-
tein cholesterol (LDL) concentrations were calculated with
the Friedwald formula [12]. Fasting glucose was measured
by the glucose oxidase method. All biochemical parame-
ters were determined on an automated Synchron CX7
Clinical System (Beckman, Fullerton, CA). Plasma insulin
was assayed by IRMA Insulin kit (Immunotech, France).
Insulin resistance (IR) was evaluated with the homeostasis
model assessment (HOMA) using the following equation:
HOMA-IR= (Fasting insulin (μUI/ml) * Fasting glucose
(mmol/l) / 22.5 as per method of Matthews et al. [13].
Concentrations of maternal cytokines, including TNF-α
and IL-6 were measured by ELISA-kits (Immunotech,
France). Adiponectin concentrations were measured also
by ELISA (R & D System, USA) according to the manufac-
turer’s instructions.
Laser Doppler iontophoresis and hemodynamic
measurement of FSBF
Combining Laser Doppler flow measurements with
iontophoresis of vasoactive agents is a promising non-
invasive tool and an attractive technique for studying the
hemodynamic of the skin microcirculation in humans.
The protocol used is well-explained in the study of
Miâdi-Messaoud et al. [8]. The equipments used were the
following: Laser Doppler flowmeter (Periflux PF5000;
Perimed, Stockholm, Sweden), electrode chamber (PF383;
Primed Stockholm, Sweden) and acetylcholine chloride
(Sigma Aldrich, Switzerland).
The following parameters were determined:
 Basal perfusion index (skin temperature = 33°C,
arbitrary unit) during the second 2 min without Ach
infusion
 Perfusion index after the third dose of Ach
iontophoresis, i.e. the maximal endothelial response
(arbitrary unit)
 Maximum perfusion index after heat hyperthermia
and without Ach infusion (skin temperature = 44°C,
arbitrary unit)
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curves (CCRC) of FSBF to Ach were obtained for each
individual. For all groups, FSBF endothelium-dependant
was defined as the maximal blood flow in response to
Ach iontophoresis divided by the mean baseline blood
flow expressed in percent.
Statistical analysis
Statistical analyses are performed using SPSS 17.0. All
variables measured are reported as mean (M) ± standard
deviation (SD), by applying Kolmogrov-Smirnov normal-
ity test; we found that all variables are normally distrib-
uted so we applied parametric analyses using the student
t-test. Spearman correlation was performed on all pa-
rameters with FSBF. All correlated variables are intro-
duced in linear regression, for relationship between
FSBF as dependant variable and the inflammatory cyto-
kine as independent variables in ascendant model, to as-
sess the magnitude of their individual effects on FSBF. A
p-value < 0.05 was considered statistically significant for
all tests.
Results
Anthropometric parameters of the two groups are
shown in Table 1. No significant differences in all
anthropometric parameters between two groups were
observed as regards age, weight, BMI, systolic blood
pressure, diastolic blood pressure, waist circumference
and hip circumference. In the two groups gestational age
is homogenous, and there is no large variability.
Metabolic parameters are shown in Table 2. As
expected, glucose at fasting, HOMA-IR and HbAc
(glycated hemoglobin) were significantly higher in GDM
group compared to control, whereas fasting insulinemia
was insignificantly increased in GDM group.
TC, creatinine were significantly higher in GDM group
compared to control whereas triglyceride and LDL levels
were higher in the same group but were not significantly
different with the control group. The levels of HDL, Apo
A1, adiponectin and urea were significantly decreased in
GDM group compared to control.Table 1 Anthropometric parameters
Control subjects
Age (years) 28.3 ± 4.24
Weight (kg) 76.1 ± 3.23
Height (m) 1.6 ± 0.06
BMI (kg/m2) 29.7 ± 2.23
Systolic blood pressure (mmHg) 111.13 ± 5.6
Diastolic blood pressure (mmHg) 61.46 ± 7.9
Waist circumference (cm) 107.7 ± 11.66
Hip circumference (cm) 109.7 ± 6.7
Data are M ± SD. n=24 control subjects; n=28 GDM subjects.FSBF was significantly decreased in GDM group com-
pared with control. Significant correlations among all
groups regarding FSBF with biochemical and inflamma-
tory parameters are regrouped in Table 3. Positive cor-
relation retained, with FSBF, was urea, ApoA1 and
adiponectin. Negative correlation was obtained with cre-
atinine, HbAc, HOMA-IR, IL-6 and TNF-α was retained
with dependant variable, FSBF.
In order to evaluate the independent contribution of
biochemical and inflammatory parameters to predict
FSBF, we performed an ascendant regression analysis
only of IL-6, TNF-α and adiponectine in the model with a
strong linear relationship with FSBF (r2 = 0.43, p < 0.0001),
FSBF = 1738.57 – 0.372 * IL-6 – 0.249 * TNF-α + 0.246 *
adiponectin.
Discussion
The results of this study show the following new find-
ings: 1) as compared with control pregnant women,
non-obese GDM women show an impaired FSBF; and
2) FSBF is inversely correlated to pro-inflammatory cyto-
kines, IL-6 and TNF-α, and in parallel related to
adiponectin.
FSBF, an endothelium-dependant phenomenon, was ex-
amined at supine position. Ach induced vasodilatation of
skin microcirculation by iontophoretic transdermal ad-
ministration, involving agonistic endothelium-dependent
response [14]. Ach provokes increases in the skin laser
Doppler blood flow signal in a dose-dependent manner
[15] and with an acceptable reproducibility (coefficients
of variation between 10 and 17%) [16,17]. This tech-
nique was the method of choice for pregnant women in
view of its non-invasiveness and the comfortable condi-
tions of realization.
Although, many studies have explored the endothe-
lium function with GDM women, but, to our know-
ledge, no previous study has assessed in vivo the
maternal endothelial function in non-obese pregnan-
cies, complicated by GDM, using combined Laser Dop-
pler blood flow measurement with iontophoresis of
vasoactive agent like Ach.GDM p-value
31.7 ± 5.5 0.064
76 ± 2.3 0.239
1.63 ± 0.04 0.200
28.5 ± 1.8 0.440
113.01 ± 9.28 0.074
61.97± 10 0.298
115.5 ± 10.58 0.613
116.1 ± 11.92 0.036
Table 2 Comparison of metabolic and vascular characteristics between control subjects and GDM subjects
Control subjects GDM p-value
Fasting glucose (mmol/l) 5.03 ± 0.46 5.42 ± 1.64* 0.01
Fasting insulinemia (μUI/ml) 10.59 ± 11.1 13.19 ± 10.05 0.67
Triglyceride (mmol/l) 1.99 ± 0.23 2.4 ± 0.93 0.38
Total cholesterol (mmol/l) 5.12 ± 1.26 5.43 ± 1.54** <0.0001
HDL cholesterol (mmol/l) 1.47 ± 0.55 1.31 ± 0.3* 0.018
LDL cholesterol (mmol/l) 2.59 ± 1.39 2.94 ± 1.27 0.47
Apo A1 (g/l) 1.90 ± 0.7 1.50 ± 0.34** 0.001
Apo B (g/l) 1.36 ± 0.5 1.22 ± 0.43 0.64
Urea (mmol/l) 3.83 ± 1.16 2.44 ± 0.89* 0.050
Creatinine (μmol/l) 49.99 ± 0.15 50.74 ± 8.76 0.6
HbAc (%) 5.27 ± 0.5 6.7 ± 1.21* 0.002
HOMA-IR 1.53 ± 0.51 2.38 ± 1.39* 0.02
Adiponectin (μg/ml) 10.02 ± 1.1 8.58 ± 1.7* 0.01
IL-6 (pg/ml) 53.17 ± 1.45 77.84 ± 10.98* 0.002
TNF-α (pg/ml) 61.75 ± 6.5 71.63 ± 12.33 0.091
C-reactive protein (mg/dl) 0.86 ± 1.1 0.80 ± 1.4 0.716
FSBF endothelium-dependent (%) 1176.38 ± 531.67 344.59 ± 305.81* 0.037
Data are M ± SD. n=24 control subjects; n=28 GDM subjects and significant difference is as follow: *p<0.05, **p<0.001.
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women with pregnancies complicated by GDM have im-
paired endothelial function. This malfunction should be
related to deregulation of glucose metabolism according
to the literature [18]. There are several investigators who
have also reported this impaired resistant in euglycemic
women with previous GDM [18]. One of the principal
objectives with regard to diabetic patients, at high-risk
pregnancies, is to obtain an euglycemic level.
Besides, endothelial function in diabetes has been attrib-
uted mainly to hyperglycemia [19,20] but also, and re-
cently to subclinical inflammation [7]. It is interesting to
note that among all subjects, FSBF is strongly and posi-
tively related to anti-inflammatory adiponectin (r = 0.468,
P < 0.0001), as shown in Figure 1, and negatively related
to the levels of pro-inflammatory cytokines, IL-6 andTable 3 Spearman’s bivariate correlation coefficients









TNF-α −0.426 <0.0001TNF-α (respectively, r = −0.564, p < 0.0001; r= − 0.426,
p < 0.0001), as shown respectively in Figures 2 and 3.
In our study, insulin resistance, performed with HOMA
system, was significantly higher in GDM group compared
with control, and it was negatively correlated with FSBF. It
has been reported that there is a relationship between in-
sulin resistance and inflammatory status as described by
Dandona et al. [21].
According to our results, it seems that the GDM pa-
tients might suffer from metabolic syndrome, markedFigure 1 Linear regression analysis of percentage increase in
FSBF and adiponectin.
Figure 2 Linear regression analysis of percentage increase in
FSBF and IL-6.
Mrizak et al. Lipids in Health and Disease 2013, 12:93 Page 5 of 7
http://www.lipidworld.com/content/12/1/93with elevated triglyceride and LDL concentration, low
HDL concentrations. This physiological change might
be the result of an elevated triglyceride load in the HDL
particles by the action of hepatic lipase which hydroly-
ses the triglycerides [21]. The small HDL particles,
which have lost triglyceride, are filtered by the kidney,
resulting in a decrease in apolipoprotein (Apo) A and
HDL concentrations. Moreover, there are reports that
insulin may promote ApoA gene transcription [22,23].
Hence, insulin resistance may be related to diminished
ApoA biosynthesis, which seems to be the case in our
GDM subjects [24].
In the light of our results, we can propose that there
exists a tridimensional relationship between FSBF,Figure 3 Linear regression analysis of percentage increase in
FSBF and TNF-α.insulin resistance and inflammatory status in GDM
group [21,25]. However, the relationship between pro-
inflammation and endothelial function is not well-
understood. In human endothelial cells, L-arginine is
taken up via membrane transport systems grouped a
family of proteins known as cationic amino acid trans-
porters (CATs) (hereafter referred as “CATs family”) [26]
whose expression and activity, and the mechanisms
modulating these phenomena, have been extensively de-
scribed [27-32], including in the human placenta [33,34].
In another hand, it is now established that GDM are
pathological conditions altering hCAT (cationic amino
acid transporter-1)-mediated arginine transport and
eNOS (endothelial nitric oxide synthase) synthesis of
NO in human feto-placental vasculature, due to abnor-
mal signaling pathway leading to altered vascular re-
activity and changes in umbilical vessels blood flow from
and to fetus with serious consequence on its growth
[35]. Altogether these findings could be crucial for fetal
insulin modulation of endothelial-derived NO synthesis
in human umbilical vessels from pregnancy diseases as-
sociated with hyperinsulinemia, such as GDM, and other
states of insulin resistance [27,36-39].
It has been reported that Akt2-null mice develop insulin
resistance and mild hyperglycemia with hyperinsulinemia
[40] as Akt2 is a key protein involved in signal transduc-
tion. Besides, the phosphorylation of Akt2 can be induced
by TNF-α and IL-6 which have recently been implicated
in inducing SOCS-3 [41-43], a protein known to interfere
with tyrosine phosphorylation of the insulin receptor and
IRS-1 (insulin receptor substrate 1) [44]. This, in turn, re-
duces the activation of Akt (protein kinase B), which nor-
mally causes the translocation of the insulin-responsive
glucose transporter, Glut-4, to the plasma membrane. It
also induces the phosphorylation of the enzyme NOS and
its activation to generate NO [42].
As discussed above, NO is a key mediator of vascular
health, promoting smooth muscle relaxation and exerting
anti-inflammatory and antithrombotic effects. Under nor-
mal conditions, eNOS transfers electrons to L-arginine to
produce citrulline and NO. Decreased NO availability has
been observed in clinical studies of patients with insulin
resistance [45,46].
What is the origin of this pro-inflammatory state in
the GDM women? It is possible that during insulin re-
sistance, increased IL-6 not only diminishes insulin
sensitivity but by suppressing insulin signal transduc-
tion also interferes with anti-inflammatory effect of in-
sulin, and might favour inflammation during insulin
resistance [47].
Indeed, novel non-metabolic actions have been attrib-
uted to insulin, like anti-inflammatory effect [21]. Insulin
has been shown to suppress several pro-inflammatory
transcription factors, such as nuclear factor (NF-κB),
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protein-1 (AP-1) and the corresponding genes which
mediate inflammation [47,48].
The pro-inflammatory state induces insulin resist-
ance, leading to clinical and biochemical manifestations
of the metabolic syndrome. This resistance to insulin
action promotes inflammation further through an in-
crease in FFA (Free fatty acid) concentration and inter-
feres with the anti-inflammatory effect of insulin [21].
The increase of FFA may be the result of hormonal
modifications until gestation like Human placental
lactogen (HPL).
Insulin secretion in women with GDM is defective
and, therefore, is unable to rise adequately to compen-
sate for the insulin resistance; the result is hypergly-
cemia. The mechanism by which elevated plasma FFA
levels cause insulin resistance in skeletal muscle includes
intramyocellular accumulation of diacylglycerol, which
activates protein kinase C (the b II and d isoforms). This
results in reduction of tyrosine phosphorylation of the
insulin receptor substrate-1 and inhibits activation of
phosphoinositol-3 kinase, an enzyme that is essential for
normal insulin-stimulated glucose uptake [49,50].
Inflammatory cytokines have a pivotal role in placental
function throughout pregnancy. Moreover, the progres-
sive development of insulin resistance during pregnancy
is due, in part, to placental cytokines such as TNF-α [51]
and leptin [52]. Studies on the expression of inflamma-
tory genes in GDM women have demonstrated major
changes in placental gene expression [53].
Conclusion
The particularity of our study is that the studied popula-
tion was not obese; however, the results showed clearly
that the GDM group suffered from dyslipidemia, insulin
resistance, pro-inflammatory status and exhibited endo-
thelial dysfunction. Our study is limited by the number
of subjects and these results should be supported by re-
searches that extend the number of recruited.
Abbreviations
Akt: Protein kinase B; Apo A1: Lipoprotein 1; Apo B: Lipoprotein B;
ELISA: Enzyme linked immunosorbent assay; eNOS: Endothelial nitric oxide
synthase; Erg1: Early growth response protein 1; FFA: Free fatty acid;
FSBF: Forearm skin blood flow; GDM: Gestational diabetes mellitus;
HbAc: Glycated hemoglobin; h-CAT: Cationic amino acid transporter 1;
HOMA-IR: Homeostasis model assessment-insulin resistance; IL-6: Interleukin
6; IRMA: Immunoradiometric assay; IRS-1: Insulin receptor substrate 1;
NF-κB: Nuclear factor-kappa B; NO: Nitric oxide; SCOS-3: Suppressor of
cytokine signaling 3; T2D: Type 2 diabetes; TC: Total cholesterol;
TG: Triglyceride; TNF-α: Tumor necrosis factor alpha.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MI was in charge of the practical work and prepared major parts of the
manuscript. AA collected and analyzed data with the involvement of MI.
FM participated in interpretation of the gynecology function. DH interpretedLaser Doppler Data. BA and BI conducted biochemical analyses. MZ
conducted hormonal analyses. TZ and KNA planned and organized the study
and contributed to the revisions and the final drafts of the manuscripts. All
authors read and approved the final manuscript.
Acknowledgements
We would like to thank the Department of Gynecology, Farhat Hached
University Hospital Sousse, Tunisia, under the direction of Professor Khairi
Hédi, for the kind collaboration. We would also like to express our sincere
thanks to Professor Rebai Ahmed Centre of Biotechnology of Sfax, Tunisia.
Writing group
Ines Mrizak, Amel Arfa, Mariem Fekih, Haythem Debbabi, Ali Bouslema, Imen
Boumaiza, Monia Zaouali, Naim A Khan and Zouhair Tabka.
Author details
1Department of Physiology and Functional Exploration, Farhat Hached
University Hospital, Sousse, Tunisia. 2Department of Gynecology, Farhat
Hached University Hospital Sousse, Sousse, Tunisia. 3Department of
Biochemistry, Sahloul University Hospital Sousse, Sousse, Tunisia. 4INSERM
U866, Physiology of Nutrition & Toxicology, University of Burgundy, Faculty
of Life Sciences, Dijon, France.
Received: 8 December 2012 Accepted: 10 June 2013
Published: 27 June 2013
References
1. American Diabetes Association: Diagnosis and Classification of Diabetes
Mellitus. Diabetes Care 2006, 29(1):43–48.
2. Hanna FW, Peters JR, Harlow J, Jones PW: Gestational diabetes screening
and glycaemic management; national survey on behalf of the
Association of British Clinical Diabetologists. QJM 2008, 101(10):777–784.
3. Wolf M, Sauk J, Shah A, Vossen Smirnakis K, Jimenez-Kimble R, Ecker JL,
Thadhani R: Inflammation and glucose intolerance: a prospective study
of gestational diabetes mellitus. Diabetes Care 2004, 27(1):21–27.
4. Richardson AC, Carpenter MW: Inflammatory mediators in gestational
diabetes mellitus. Obstet Gynecol Clin North Am 2007, 34(2):213–224.
5. Black PH: The inflammatory consequences of psychologic stress:
relationship to insulin resistance, obesity, atherosclerosis and diabetes
mellitus, type II. Med Hypotheses 2006, 67(4):879–891.
6. Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW: Subclinical
inflammation and vascular dysfunction in women with previous gestational
diabetes mellitus. J Clin Endocrinol Metab 2005, 90(7):3983–3988.
7. López-Tinoco C, Roca M, Fernández-Deudero A, García-Valero A, Bugatto F,
Aguilar-Diosdado M, Bartha JL: Cytokine profile, metabolic syndrome and
cardiovascular disease risk in women with late-onset gestational
diabetes mellitus. Cytokine 2012, 58(1):14–19.
8. Miâdi-Messaoud H, Chouchane A, Abderrazek E, Debbabi H, Zaouali-Ajina M,
Tabka Z, Ben-Jebria A: Obesity-induced impairment of endothelium-
dependent vasodilation in Tunisian women. Int J Obes 2010, 34(2):273–279.
9. Debbabi H, Bonnin P, Ducluzeau PH, Lefthériotis G, Levy BI: Noninvasive
assessment of endothelial function in the skin microcirculation.
Am J Hypertens 2010, 23(5):541–546.
10. National Diabetes Data Group: Classification and diagnosis of diabetes
mellitus and other categories of glucose intolerance. Diabetes 1979,
28(12):1039–1057.
11. O'Sullivan JB: Criteria for the glucose tolerance test in pregnancy.
Diabetes 1964, 13:278–285.
12. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of
low-density lipoprotein cholesterol in plasma without use of preparative
ultracentrifuge. Clin Chem 1972, 18:499–502.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC:
Homeostasis model assessment: insulin resistance and beta-cell function
from fasting plasma glucose and insulin concentrations in man.
Diabetologia 1985, 28:412–419.
14. Morris SJ, Shore AC: Skin blood flow responses to the iontophoresis of
acetylcholine and sodium nitroprusside in man: possible mechanisms.
J Physiol 1996, 496(2):531–542.
15. Christen S, Delachaux A, Dischl B, Golay S, Liaudet L, Feihl F, Waeber B:
Dose-dependent vasodilatory effects of acetylcholine and local warming
on skin microcirculation. J Cardiovasc Pharmacol 2004, 44(6):659–664.
Mrizak et al. Lipids in Health and Disease 2013, 12:93 Page 7 of 7
http://www.lipidworld.com/content/12/1/9316. Newton DJ, Khan F, Belch JJ: Assessment of microvascular endothelial
function in human skin. Clin Sci 2001, 101(6):567–572.
17. Kubli S, Waeber B, Dalle-Ave A, Feihl F: Reproducibility of laser Doppler
imaging of skin blood flow as a tool to assess endothelial function.
J Cardiovasc Pharmacol 2000, 36(5):640–648.
18. Paradisi G, Biaggi A, Ferrazzani S, De Carolis S, Caruso A: Abnormal
carbohydrate metabolism during pregnancy : association with
endothelial dysfunction. Diabetes Care 2002, 25(3):560–564.
19. Emery SP, Levine RJ, Qian C, Ewell MG, England LJ, Yu KF, Catalano PM,
CPEP study group: Twenty-four-hour urine insulin as a measure of
hyperinsulinaemia/insulin resistance before onset of pre-eclampsia and
gestational hypertension. BJOG 2005, 112(11):1479–1485.
20. Barden A, Singh R, Walters BN, Ritchie J, Roberman B, Beilin LJ: Factors
predisposing to pre-eclampsia in women with gestational diabetes.
J Hypertens 2004, 22(12):2371–2378.
21. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic
syndrome: a comprehensive perspective based on interactions between
obesity, diabetes, and inflammation. Circulation 2005, 111(11):1448–1454.
22. Groenendijk M, Cantor RM, Blom NH, Rotter JI, de Bruin TW, Dallinga-Thie
GM: Association of plasma lipids and apolipoproteins with the insulin
response element in the apoC-III promoter region in familial combined
hyperlipidemia. J Lipid Res 1999, 40(6):1036–1044.
23. Klein BE, Klein R, Lee KE: Components of the metabolic syndrome and risk
of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care
2002, 25(10):1790–1794.
24. Mooradian AD, Haas MJ, Wong NC: Transcriptional control of apolipoprotein
A-I gene expression in diabetes. Diabetes 2004, 53(3):513–520.
25. Huda SS, Brodie LE, Sattar N: Obesity in pregnancy: prevalence and
metabolic consequences. Semin Fetal Neonatal Med 2010, 15(2):70–76.
26. Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y: CATs and HATs:
the SLC7 family of amino acid transporters. Pflugers Arch 2004,
447(5):532–542.
27. Sobrevia L, González M: A role for insulin on L-arginine transport in fetal
endothelial dysfunction in hyperglycaemia. Curr Vasc Pharmacol 2009,
7(4):467–474.
28. González M, Gallardo V, Rodríguez N, Salomón C, Westermeier F, Guzmán-
Gutiérrez E, Abarzúa F, Leiva A, Casanello P, Sobrevia L: Insulin-stimulated L-
arginine transport requires SLC7A1 gene expression and is associated with
human umbilical vein relaxation. J Cell Physiol 2011, 226(11):2916–2924.
29. Tsitsiou E, Sibley CP, D'Souza SW, Catanescu O, Jacobsen DW, Glazier JD:
Homocysteine transport by systems L, A and y+L across the microvillous
plasma membrane of human placenta. J Physiol 2009, 587(Pt 16):4001–4013.
30. Flores C, Rojas S, Aguayo C, Parodi J, Mann G, Pearson JD, Casanello P,
Sobrevia L: Rapid stimulation of L-arginine transport by D-glucose
involves p42/44(mapk) and nitric oxide in human umbilical vein
endothelium. Circ Res 2003, 92(1):64–72.
31. Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between
insulin resistance, obesity and diabetes. Trends in Immunology 2004, 25(1):4–7.
32. Athyros VG, Hatzitolios A, Karagiannis A, Didangelos TP, Iliadis F, Dolgyras S,
Vosnakidis T, Vasiliadis P, Malias I, Tziomalos K, Samouilidou M, Mikhailidis
DP: Initiative for a new diabetes therapeutic approach in a
Mediterranean country: the INDEED study. Curr Med Res Opin 2009,
25(8):1931–1940.
33. Dye JF, Vause S, Johnston T, Clark P, Firth JA, D'Souza SW, Sibley CP, Glazier
JD: Characterization of cationic amino acid transporters and expression
of endothelial nitric oxide synthase in human placental microvascular
endothelial cells. FASEB J 2004, 18(1):125–127.
34. Arancibia-Garavilla Y, Toledo F, Casanello P, Sobrevia L: Nitric oxide
synthesis requires activity of the cationic and neutral amino acid
transport system y+L in human umbilical vein endothelium. Exp Physiol
2003, 88(6):699–710.
35. Leiva A, Pardo F, Ramírez MA, Farías M, Casanello P, Sobrevia L:
Fetoplacental vascular endothelial dysfunction as an early phenomenon
in the programming of human adult diseases in subjects born from
gestational diabetes mellitus or obesity in pregnancy. Exp Diabetes Res
2011, doi:10.1155/2011/349286. Article ID 349286.
36. Westermeier F, Puebla C, Vega JL, Farías M, Escudero C, Casanello P,
Sobrevia L: Equilibrative nucleoside transporters in fetal endothelial
dysfunction in diabetes mellitus and hyperglycaemia. Curr Vasc
Pharmacol 2009, 7(4):435–449.37. Westermeier F, Salomón C, González M, Puebla C, Guzmán-Gutiérrez E,
Cifuentes F, Leiva A, Casanello P, Sobrevia L: Insulin restores gestational
diabetes mellitus-reduced adenosine transport involving differential
expression of insulin receptor isoforms in human umbilical vein
endothelium. Diabetes 2011, 60(6):1677–1687.
38. Sobrevia L, Abarzúa F, Nien JK, Salomón C, Westermeier F, Puebla C,
Cifuentes F, Guzmán-Gutiérrez E, Leiva A, Casanello P: Review: Differential
placental macrovascular and microvascular endothelial dysfunction in
gestational diabetes. Placenta 2011, 32(2):S159–S164.
39. Ukkola O, Santaniemi M: Adiponectin: a link between excess adiposity
and associated comorbidities? J Mol Med 2002, 80:696–702.
40. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB 3rd, Kaestner KH,
Bartolomei MS, Shulman GI, Birnbaum MJ: Insulin resistance and a
diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2
(PKB beta). Science 2001, 292(5522):1728–1731.
41. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW,
Mooney RA: Suppressor of cytokine signaling-3 (SOCS-3), a potential
mediator of interleukin-6-dependent insulin resistance in hepatocytes.
J Biol Chem 2003, 278(16):13740–13746.
42. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM:
Activation of nitric oxide synthase in endothelial cells by Akt-dependent
phosphorylation. Nature 1999, 399(6736):601–605.
43. Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ,
Hotamisligil GS, Van Obberghen E: SOCS-3 inhibits insulin signaling and is
up-regulated in response to tumor necrosis factor-alpha in the adipose
tissue of obese mice. J Biol Chem 2001, 276:47944–47949.
44. Rui L, Yuan M, Frantz D, Shoelson S, White MF: SOCS-1 and SOCS-3 block
insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2.
J Biol Chem 2002, 277:42394–42398.
45. Segura J, Campo C, Ruilope LM, Rodicio JL: Do we need to target
“prediabetic” hypertensive patients? J Hypertens 2005, 23(12):2119–2125.
46. Sowers JR, Frohlich ED: Insulin and insulin resistance: impact on blood
pressure and cardiovascular disease. Med Clin North Am 2004, 88(1):63–82.
47. Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between
insulin resistance, obesity and diabetes. Trends Immunol 2004, 25(1):4–7.
48. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P: Insulin inhibits the
pro-inflammatory transcription factor early growth response gene-1
(Egr)-1 expression in mononuclear cells (MNC) and reduces plasma
tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1)
concentrations. J Clin Endocrinol Metab 2002, 87(3):1419–1422.
49. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad
S: Insulin inhibits intranuclear nuclear factor kappaB and stimulates
IkappaB in mononuclear cells in obese subjects: evidence for an anti-
inflammatory effect? J Clin Endocrinol Metab 2001, 86(7):3257–3265.
50. Sivan E, Boden G: Free fatty acids, insulin resistance, and pregnancy.
Curr Diab Rep 2003, 3(4):319–322.
51. Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier JC, Huston-Presley L,
Friedman JE, Kalhan SC, Catalano PM: TNF-alpha is a predictor of insulin
resistance in human pregnancy. Diabetes 2002, 51(7):2207–2213.
52. Hauguel-de Mouzon S, Guerre-Millo M: The placenta cytokine network
and inflammatory signals. Placenta 2006, 27(8):794–798.
53. Radaelli T, Lepercq J, Varastehpour A, Basu S, Catalano PM, Hauguel-De
Mouzon S: Differential regulation of genes for fetoplacental lipid
pathways in pregnancy with gestational and type 1 diabetes mellitus.
Am J Obstet Gyneco 2009, 201(2):209e1–209e10.
doi:10.1186/1476-511X-12-93
Cite this article as: Mrizak et al.: Inflammation and impaired
endothelium-dependant vasodilatation in non obese women with
gestational diabetes mellitus: preliminary results. Lipids in Health and
Disease 2013 12:93.
